Effects of Tourniquet Use on Physical Function and Performance in Primary Total Knee Arthroplasty

June 27, 2013 updated by: Rasmus Lohmann-Jensen, MSc, University of Southern Denmark

Effects of Tourniquet Use on Physical Function and Performance in Primary Total Knee Arthroplasty: A Randomized Controlled Trial

Background:

Osteoarthritis (OA) is the most common joint disease that causes symptomatic health problems in the elderly population. For some patients with knee OA, total knee arthroplasty (TKA) may be the only option that offers the possibility of reestablishing the patient's life quality.

Surgery of TKA usually takes place in a complete bloodless field established by a tourniquet around the thigh. The method aims to reduce blood loss and give the surgeon better visibility during the operation. The method is, however, not without side effects as patients often experience severe pain and swollen leg in the time after surgery. Furthermore, has the method shown decidedly muscle- and nerve damage followed by prolonged rehabilitation and reduced physical function.

It is, however, possible to perform the operation without the use of the tourniquet.

Aim and hypothesis:

The aim of the present study is to assess the effects of tourniquet use in TKA on physical function, early rehabilitation, pain and opioid consumption.

Hypotheses H1: TKA without tourniquet leads to better physical function and early rehabilitation.

H2: TKA without tourniquet causes less pain and opioid consumption H3: Recovery of mechanical lower limb function post TKA is faster without use of tourniquet.

Methods:

80 patients (40 in each group) all eligible for TKA will be consecutively recruited and randomized to A) TKA without tourniquet, B) TKA with tourniquet. Subjects will be evaluated before the operation (baseline) and 14 days, 3, 6 and 12 months after the operation.

The primary outcome will be the change from baseline to 3 months in self-administered knee-function (KOOS-ADL subscale). Further, will we examine a number of pre-specified secondary outcomes, which include self-rated knee-related pain, symptoms, difficulty with sports and leisure activities, and quality of life. In addition, muscle function, physical performance, and the use of pain medication will be studied

Impact of the project:

The project design of this study will enable analyses for determining the impact of operating without tourniquet and whether such an intervention can in fact improve physical function, performance and quality of life within TKA patients. The results may impact notably on the patient level and possible redefine current surgical strategies. The societal perspective of the project is to remobilize patients faster, which may reduce hospital services and absence from work.

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Odense, Denmark, 5000
        • Odense University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Knee Osteoarthritis both clinically and radiologically according to the "Ahlbäck classification system".
  • Patients who can tolerate spinal anesthesia

Exclusion Criteria:

  • Patients with rheumatoid arthritis.
  • Patients with BMI > 35.
  • History of major knee operations.
  • Malignancy.
  • Known muscle disease.
  • History of deep vain thrombosis (DVT), or other blood coagulation disorders.
  • Symptomatic bilateral OA, with planned surgery of the contra lateral knee within a year.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: TRIPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Non-tourniquet assisted TKA
The intervention group will undergo non-tourniquet assisted total knee arthroplasty, which means that blood flow to the lower limb is maintained throughout surgery.
OTHER: Tourniquet assisted TKA
The procedure involves the use of a tourniquet around the thigh. During surgery the tourniquet will be inflated above the systolic blood pressure to ensure a complete bloodless surgical field.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in self reported physical function. Assessed with the Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire subscale for, Function in Daily Living (ADL).
Time Frame: Endpoint 3 months
Further assessments: Baseline, 14 days and a 6 and 12 months follow up. KOOS is a patient-reported outcome measure with good evidence of reliability, validity and responsiveness in different population with varying pathologies, injury durations, and activity levels (http://www.koos.nu).
Endpoint 3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in the Knee injury and Osteoarthritis Outcome Score (KOOS)
Time Frame: Baseline, 14 days, 3 months (endpoint) and a 6 and 12 months follow up
The remaining 4 subscales for pain, other symptoms, function in sport and recreation, and knee related quality of life.
Baseline, 14 days, 3 months (endpoint) and a 6 and 12 months follow up
Global perceived effect (GPE) score
Time Frame: 3 months (endpoint) and a 6 and 12 months follow up
In addition to pain and physical function the assessment by the patient of a global perceived effect of the treatment is a recommended responder criterion [4]. Patients will be asked to rate possible change in their condition since the initial administration (baseline) on a 7-point Likert-scale.
3 months (endpoint) and a 6 and 12 months follow up
Change in physical performance (battery).
Time Frame: Baseline, 3 and 14 days, 3 months (endpoint) and a 6 months follow up
Physical performance-based measures will include; Passive knee range of motion, 30 s chair stand (number completed), 20 m normal-paced and fast-paced walk (time in sec.), and timed up and go (time in sec.)
Baseline, 3 and 14 days, 3 months (endpoint) and a 6 months follow up

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in mechanical muscle function
Time Frame: Baseline, 3 and 6 months
Mechanical muscle function includes; Quadriceps strength (MVC), Rate of force development, surface electromyography, force steadiness.
Baseline, 3 and 6 months
Change in 30-sec Maximal Repeated Unilateral Knee Bending
Time Frame: Baseline, 3 and 6 months
Measures the maximum number of knee bends performed on one leg in 30 seconds and the ability to execute fast stretch shortening cycles over the knee joint.
Baseline, 3 and 6 months
Change in Pain
Time Frame: Baseline and 1-14 days

Self-reported pain: Pain intensity is measured using an 11-step visual analogue scale (VAS) (0 = no pain and 10 = worst possible pain). The VAS has been demonstrated to be reliable and valid in assessing the intensity of musculoskeletal knee pain [5].

Self-reported use of pain medication: The patient's use of pain medication will be registered.

Baseline and 1-14 days
Muscle biopsies
Time Frame: Baseline
Two muscle biopsy samples (2 * 100 mg) will be acquired in a subgroup of the patients (2 x 10) during operation. One sample will be collected prior to applying the tourniquet, and a second sample will be collected prior to the removal of the tourniquet. Muscle tissue is frozen in liquid nitrogen and sent for analysis at the Institute of Sports Science and Clinical Biomechanics for mechanical characteristics, Ca2+-kinetics and markers of free oxygen radicals.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Rasmus Lohmann-Jensen, Cand. Scient, Odense University Hospital and University of Southern Denmark
  • Study Chair: Søren Overgaard, Professor, Odense University Hospital and University of Southern Denmark

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2013

Primary Completion (ANTICIPATED)

November 1, 2014

Study Completion (ANTICIPATED)

September 1, 2016

Study Registration Dates

First Submitted

June 21, 2013

First Submitted That Met QC Criteria

June 27, 2013

First Posted (ESTIMATE)

July 3, 2013

Study Record Updates

Last Update Posted (ESTIMATE)

July 3, 2013

Last Update Submitted That Met QC Criteria

June 27, 2013

Last Verified

June 1, 2013

More Information

Terms related to this study

Other Study ID Numbers

  • S-20110084

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Knee Osteoarthritis

Clinical Trials on Non-tourniquet assisted TKA

Subscribe